The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The significance of QT interval in drug development
Open accessAbstract
The duration of QT interval of the surface electrocardiogram (ECG) reflects the ventricular action potential duration (APD) which is determined mainly by the rapid component of the outward repolarizing current (IKr). This current is mediated primarily by the delayed rectifying potassium channel. Thus, the QT interval is congenitally prolonged when this current is diminished as a result of genetic mutations of this channel as for example in the Romano–Ward syndrome [1]. Reduction in this current and hence, the prolongation of the QT interval may also be acquired, resulting from electrolyte imbalance (especially hypokalaemia and/or hypomagnesaemia), endocrine dysfunction (e.g. hypothyroidism), autonomic imbalance, various disease states or most frequently, following clinical administration of drugs. Drug-induced prolongation of the QTc interval may be followed by potentially fatal proarrhythmias. More than any other adverse drug reaction in recent times, it has been responsible for the withdrawal of many drugs from the market and yet as a surrogate of proarrhythmias, it is not well understood. Regulatory decisions have resulted in rejection of some new drugs or the restriction on the clinical use of many old and other new drugs over the last decade because of their potential to prolong the QTc interval. Therefore, there are regulatory and clinical expectations of better preapproval characterization of new chemical entities (NCEs) for this potential risk which have had a very profound influence on drug development. This paper will focus on the issues that need to be addressed during drug development, strategies aimed at identifying this risk during early preclinical and clinical phases of drug development and the regulatory assessment of the potential risk, particularly the electrocardiographic data from the clinical trials. Because the actually measured QT interval changes with heart rate in the absence of any intervention, it is usual to correct the measured interval for changes in heart rates (RR interval) to derive a rate-corrected (QTc) interval, which is then used when evaluating the effect of an intervention. Clinically, the rate-correction applied most widely, and almost exclusively for years, is the Bazett's correction (QTc=QT/RR0.50), which divides the measured QT interval by the square root of the preceding RR interval. A less frequently applied rate-correction is that of Fridericia (QTc=QT/RR0.33) which divides the measured QT interval by the cube root of the preceding RR interval. Both these corrections standardize the measured QT interval to an RR interval of 1 s (heart rate of 60 beats min−1). When corrected by Bazett's formula, on historical and epidemiological grounds, the widely accepted upper limits of normal QTc interval are 450 ms in adult males, 470 ms in adult females and 460 ms in children between 1 and 15 years of age (regardless of gender). Unless stated otherwise, the QTc interval referred to in this paper is the interval as corrected by Bazett's formula. Drug-induced prolongation of QTc interval is expected with class III antiarrhythmic drugs which are intended to produce their desired therapeutic benefit by blocking IKr, delaying ventricular repolarization and, therefore, increasing myocardial refractory period. Typical examples of these drugs include sotalol, bretylium, ibutilide, dofetilide, azimilide, sematilide, ambasilide, almokalant, N-acetyl-procainamide, fenoxedil and terikalant. Excessive QTc interval prolongation in the right setting (see risk modifying factors below) can be proarrhythmic and degenerate into a potentially fatal ventricular tachyarrhythmia known as torsade de pointes (TdP), a unique polymorphic form of ventricular tachycardia which (by definition) is associated with concomitant prolongation of QTc interval [2]. TdP is triggered by the appearance of early after-depolarizations (EADs), mediated by slow inward calcium current, during the late phase 2 of the prolonged action potential. Therefore, as an extension of their pharmacological effect, this iatrogenic proarrhythmia may be expected in some individuals following the use of antiarrhythmic drugs, which possess class III (potassium channel blocking) activity. For example, the incidence of TdP is variously estimated to be 0.5% to 8.8% with quinidine [3] and 2.6% to 4.1% with sotalol [4]. The incidence is higher in combination preparations of sotalol that include a thiazide diuretic, which induces hypokalaemia [5], and lower with racemic sotalol in contrast to (+)-(S)-sotalol because of the β-adrenoceptor blocking activity of (−)-(R)-sotalol present in the former. It is plainly evident that the balance between the therapeutic antiarrhythmic effect and the potentially fatal proarrhythmic effect of QTc interval prolongation is a very delicate one, depending not only on the drug concerned and its plasma concentration but also on a number of host modifying factors. These factors include female gender, electrolyt
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Mechanism of the Cardiotoxic Actions of Terfenadine
Woosley, R. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500120070028 · Cited by 646
Hammond, T. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00310-2 · Cited by 117
Cited by
Schüttler, J., Eisenried, A., Lerch, M., Fechner, J., Jeleazcov, C., & Ihmsen, H. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003103 · Cited by 338
Goldstein, D. B., Tate, S. K., & Sisodiya, S. M. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1229 · Cited by 312
Charbit, B., Albaladejo, P., Funck-Brentano, C., Legrand, M., Samain, E., & Marty, J. (2005) · Anesthesiology · doi:10.1097/00000542-200506000-00006 · Cited by 253
Modeling Rett Syndrome Using TALEN-Edited MECP2 Mutant Cynomolgus Monkeys
Chen, Y., Yu, J., Niu, Y., Qin, D., Liu, H., Li, G., Hu, Y., Wang, J., Lu, Y., Kang, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.035 · Cited by 204
Castelletti, S., Dagradi, F., Goulene, K., Danza, A. I., Baldi, E., Stramba-Badiale, M., & Schwartz, P. J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.097 · Cited by 63
Metadata
- Authors
- Shah, R. R.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2002-08
- Volume
- 54
- Issue
- 2
- Pages
- 188-202
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2128338810
- Cited by
- 231
- References
- 4
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The significance of QT interval in drug development. https://app.cochat.ai/papers/10.1046/j.1365-2125.2002.01627.x
- The paper
- Shah, R. R. (2002). The significance of QT interval in drug development. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2002.01627.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.